{"title":"Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index.","authors":"Koji Jimbo,Ayumu Ito,Hirona Ichimura,Junichi Kuroda,Shohei Andoh,Aki Sato,Kazuaki Yokoyama,Takahiro Fukuda,Kaoru Uchimaru,Yasuhito Nannya","doi":"10.1038/s41408-025-01367-w","DOIUrl":"https://doi.org/10.1038/s41408-025-01367-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"36 1","pages":"166"},"PeriodicalIF":12.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Samaneh Maleknia,Sanam Rezaei Benam,Greg Ahmann,Rafael Fonseca,Diane F Jelinek,Reza Shahbazi
{"title":"Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression.","authors":"Samaneh Maleknia,Sanam Rezaei Benam,Greg Ahmann,Rafael Fonseca,Diane F Jelinek,Reza Shahbazi","doi":"10.1038/s41408-025-01362-1","DOIUrl":"https://doi.org/10.1038/s41408-025-01362-1","url":null,"abstract":"Multiple myeloma (MM) is characterized by the clonal proliferation of plasma cells in the bone marrow. Although the precise molecular mechanisms differentiating men and women in MM are not fully understood, uncovering these differences is crucial for improving personalized therapeutic approaches. Here, we show sex-specific dysregulation of exosomal non-coding RNAs (ncRNAs) in MM. We conducted an in-depth analysis of dysregulated ncRNAs in male and female patients, as well as MM cell lines, revealing distinct expression signatures across multiple clinical contexts, including newly diagnosed, relapse, progression, Hyperdiploid, non-Hyperdiploid, and treatment exposure. Our findings highlight the pivotal roles of lncRNAs and miRNAs in MM pathogenesis, detecting alterations in enriched pathways that influence key biological processes such as cellular proliferation, apoptosis, and gene regulation. We established a panel of ncRNAs with distinct sex-specific expression patterns, significant effects on mRNA regulation, and involvement in MM-associated biological pathways. Our results demonstrate that exosomes provide enhanced analytical resolution for detecting non-coding RNAs, enabling more sensitive and precise identification of transcriptomic alterations. These results suggest that sex-specific dysregulation of ncRNAs may contribute to differences in MM progression and therapy response. Ultimately, this study underscores the importance of exosomal ncRNA profiling in designing sex-tailored therapeutic strategies targeting dysregulated ncRNAs, paving the way for personalized medicine in MM.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"46 1","pages":"162"},"PeriodicalIF":12.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Simonetta Viviani, Chiara Pavoni, Sally F Barrington, Luca Guerra, Heiko Schöder, Peter Johnson, Amy A Kirkwood, Deborah M Stephens, Jonathan W Friedberg, Stephane Chauvie, Michael V Knopp, Stefano Luminari, Daniel Molin, Paolo Corradini, Andrea Gallamini, Alessandro Rambaldi, Corrado Tarella
{"title":"Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials.","authors":"Simonetta Viviani, Chiara Pavoni, Sally F Barrington, Luca Guerra, Heiko Schöder, Peter Johnson, Amy A Kirkwood, Deborah M Stephens, Jonathan W Friedberg, Stephane Chauvie, Michael V Knopp, Stefano Luminari, Daniel Molin, Paolo Corradini, Andrea Gallamini, Alessandro Rambaldi, Corrado Tarella","doi":"10.1038/s41408-025-01364-z","DOIUrl":"https://doi.org/10.1038/s41408-025-01364-z","url":null,"abstract":"<p><p>PET after 2 ABVD cycles (PET-2) is widely adopted to select patients with classical Hodgkin lymphoma (cHL), who might benefit from intensifying or de-escalating therapy. Prolonged progression-free survival (PFS) has been reported in PET-2 positive patients switched to escalated BEACOPP (eBEACOPP) or BEACOPP-14. Nevertheless, the subgroup of patients with a PET-2 scored 5 according to Deauville score (PET-2 DS5) are known to poorly benefit from treatment intensification. To elucidate PET-2 DS5 outcome along with possible predictive factors of response to intensification, a pooled analysis from three multicenter trials, GITIL/FIL HD0607, RATHL, and SWOG S0816, was conducted. PFS and overall survival (OS) were assessed after 41-month median follow-up, the prognostic value of clinical, laboratory, and PET parameters at diagnosis was evaluated. Among 2231 patients, 136 (6%) PET-2 DS5 patients were identified. Their 3-year PFS was 32% (95% CI, 25-42), while the 3-year OS was 82% (95% CI, 75-89). In multivariate analysis low lymphocyte (< 600/mm<sup>3</sup>) counts were adversely associated with PFS, whereas age ≥ 45 years and leukocytes cells count <15 × 103/μL were barely associated with short OS. The study confirms on a suitable cohort of PET-2 DS5 patients, that this high-risk cHL subgroup has an inadequate response to treatment intensification. Nevertheless, PET-2 DS5 patients may still have good outcome after subsequent salvage treatments with > 80% survival at 3 years, thus excluding a real disease refractoriness. Few distinct parameters may have specific prediction for PFS or OS.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"15 1","pages":"165"},"PeriodicalIF":11.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145306833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suheil Albert Atallah-Yunes,Thomas M Habermann,Matthew J Rees,Lay She Ng,Urshila Durani,Yucai Wang,Rebecca L King,Arushi Khurana
{"title":"EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity.","authors":"Suheil Albert Atallah-Yunes,Thomas M Habermann,Matthew J Rees,Lay She Ng,Urshila Durani,Yucai Wang,Rebecca L King,Arushi Khurana","doi":"10.1038/s41408-025-01375-w","DOIUrl":"https://doi.org/10.1038/s41408-025-01375-w","url":null,"abstract":"EBV-positive polymorphic B-cell lymphoproliferative disorder, NOS (poly B-LPD), is a newly defined entity in the 2022 International Consensus Classification of mature lymphoid neoplasms. Its clinical behavior and optimal treatment approach remain poorly characterized. We conducted a retrospective study of 31 patients diagnosed with EBV+ poly B-LPD at Mayo Clinic (2003-2024), excluding transplant recipients. Median age was 56 years; 71% had extranodal involvement, 68% presented with stage III/IV disease, and 52% had autoimmune conditions. Thirty-five percent (n = 11) were on immunosuppressive therapy at diagnosis, all of whom underwent reduction of immunosuppression (RIS); five underwent RIS alone, achieving four complete responses including two with central nervous system (CNS) involvement. Rituximab was effective in patients with or without prior immunosuppression. Histologic transformation to diffuse large B-cell lymphoma (DLBCL) or emergence of T-cell lymphomas occurred in immunochemotherapy non-responders or at relapse, emphasizing the role of re-biopsy in this subset of patients. At a median follow-up of 6 years, median event-free (EFS) and overall survival (OS) were 8.5 and 8.7 years, respectively. EFS was not significantly influenced by increasing IPI scores (p = 0.09), CNS involvement (p = 0.5), or immunosuppression at diagnosis (p = 0.2). There was a trend towards improved OS in patients who were on immunosuppressive therapy at diagnosis, however, this was not statistically significant, p = 0.054. This is the first study to characterize EBV+ poly B-LPD within the ICC 2022 framework. Larger studies are needed to validate these findings, define prognostic markers and guide therapy.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"119 1","pages":"163"},"PeriodicalIF":12.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David E Mery,Guido Tricot,Samer Al Hadidi,Yihao Zhan,Cody Ashby,Clyde Bailey,Eric R Siegel,Daisy V Alapat,Hongwei Xu,Sandra Mattox,Caroline Schinke,Maurizio Zangari,Sharmilan Thanendrarajan,Qing Yi,Robert Z Orlowski,Frits van Rhee,John D Shaughnessy,Fenghuang Zhan
{"title":"Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans.","authors":"David E Mery,Guido Tricot,Samer Al Hadidi,Yihao Zhan,Cody Ashby,Clyde Bailey,Eric R Siegel,Daisy V Alapat,Hongwei Xu,Sandra Mattox,Caroline Schinke,Maurizio Zangari,Sharmilan Thanendrarajan,Qing Yi,Robert Z Orlowski,Frits van Rhee,John D Shaughnessy,Fenghuang Zhan","doi":"10.1038/s41408-025-01379-6","DOIUrl":"https://doi.org/10.1038/s41408-025-01379-6","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"46 1","pages":"164"},"PeriodicalIF":12.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross Firestone, Eric Jurgens, Kevin Miller, Bruno Almeida Costa, Alexander Lesokhin, Carlyn Rose Tan, Gunjan Shah, Neha Korde, Heather Landau, Michael Scordo, Hani Hassoun, Kylee Maclachlan, Urvi Shah, Malin Hultcrantz, Andriy Derkach, Derkach Nemirovsky, Sergio Giralt, Saad Usmani, Sham Mailankody, Hamza Hashmi
{"title":"Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.","authors":"Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross Firestone, Eric Jurgens, Kevin Miller, Bruno Almeida Costa, Alexander Lesokhin, Carlyn Rose Tan, Gunjan Shah, Neha Korde, Heather Landau, Michael Scordo, Hani Hassoun, Kylee Maclachlan, Urvi Shah, Malin Hultcrantz, Andriy Derkach, Derkach Nemirovsky, Sergio Giralt, Saad Usmani, Sham Mailankody, Hamza Hashmi","doi":"10.1038/s41408-025-01383-w","DOIUrl":"10.1038/s41408-025-01383-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"15 1","pages":"161"},"PeriodicalIF":11.6,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Omer Jamy,Mobachir El Kettani,Kashish Shah,Rory M Shallis,Kendall Diebold,Alexander Coltoff,Aaron D Goldberg,Anand Patel,Jan P Bewersdorf,Charles Foucar,Yasmin Abaza,Neil Palmisiano,Adam S DuVall,Vamsi Kota,Shyam A Patel,Amer M Zeidan,Ehab Atallah,Mark R Litzow,Talha Badar
{"title":"Outcomes of older patients with TP53-mutated myeloid neoplasms.","authors":"Omer Jamy,Mobachir El Kettani,Kashish Shah,Rory M Shallis,Kendall Diebold,Alexander Coltoff,Aaron D Goldberg,Anand Patel,Jan P Bewersdorf,Charles Foucar,Yasmin Abaza,Neil Palmisiano,Adam S DuVall,Vamsi Kota,Shyam A Patel,Amer M Zeidan,Ehab Atallah,Mark R Litzow,Talha Badar","doi":"10.1038/s41408-025-01368-9","DOIUrl":"https://doi.org/10.1038/s41408-025-01368-9","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"31 1","pages":"160"},"PeriodicalIF":12.8,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jin Seok Kim, Yang Song, Wei-Ying Jen, C S Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Jae Hoon Lee, Kihyun Kim, Shigeki Ito, Jeffrey Shang-Yi Huang, Chang Ki Min, Melissa Ooi Gaik Ming, Sanjay de Mel, Cinnie Soekojo, Xinhua Li, Neha Awasthi, Yogesh Pokharkar, Brian Gm Durie, Wee-Joo Chng
{"title":"Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).","authors":"Jin Seok Kim, Yang Song, Wei-Ying Jen, C S Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Jae Hoon Lee, Kihyun Kim, Shigeki Ito, Jeffrey Shang-Yi Huang, Chang Ki Min, Melissa Ooi Gaik Ming, Sanjay de Mel, Cinnie Soekojo, Xinhua Li, Neha Awasthi, Yogesh Pokharkar, Brian Gm Durie, Wee-Joo Chng","doi":"10.1038/s41408-025-01356-z","DOIUrl":"10.1038/s41408-025-01356-z","url":null,"abstract":"<p><p>Pomalidomide has been shown to improve survival in patients with relapsed/refractory myeloma (RRMM). However, the optimal pomalidomide-based combinations in RRMM are not known. This study compared pomalidomide, cyclophosphamide, dexamethasone (PCD) with pomalidomide and dexamethasone (PD) in Asian patients with RRMM. Patients were randomly assigned to receive PCD or PD. Patients received pomalidomide at 4 mg from days 1 to 21, dexamethasone at 40 mg once a week, and those in the PCD arm received cyclophosphamide at 400 mg once weekly for three weeks. The primary endpoint was progression-free survival. One hundred and twenty-two patients were randomized (62 PCD, 60 PD). Baseline characteristics were comparable between both arms. The median prior lines of therapy were three. At a median follow-up of 13.5 (median range 9-18) months, median progression free survival was significantly longer at 10.9 months (95% confidence interval 7.1-27.7) in the PCD group compared with 5.8 months (95% CI, 4.4-6.9) in the PD group (hazard ratio 0.43; p < 0.001). Adverse events rates were similar in both arms. The most common grade ≥3 adverse events were hematological toxicities and pneumonia. 34 deaths occurred during the study (PCD: 17; PD: 17) and three were deemed to be related to study treatment. In Asian patients with RRMM after exposure to proteasome inhibitor and lenalidomide, progression-free survival was significantly prolonged with the addition of cyclophosphamide to PD, with a manageable safety profile.Trial ID: Registered at www.clinicaltrials.gov : NCT03143049.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"15 1","pages":"155"},"PeriodicalIF":11.6,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145237740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew Palmer,Garth Rauscher,Alexa Schoen,Madelyn Burkart,Ashley Dunton,Cherry Au,Ami Dave,Ahmad Nassar,Shaoshi Zhu,Alexander O'Hara,Nusrat Africawala,Amani Erra,Vinod Solipuram,Ivy Abraham,Stephanie B Tsai,Maryam Zia,Melissa L Larson,Damiano Rondelli,Jessica K Altman,Wendy Stock,Irum Khan,Olatoyosi Odenike,Anand Ashwin Patel
{"title":"Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis.","authors":"Andrew Palmer,Garth Rauscher,Alexa Schoen,Madelyn Burkart,Ashley Dunton,Cherry Au,Ami Dave,Ahmad Nassar,Shaoshi Zhu,Alexander O'Hara,Nusrat Africawala,Amani Erra,Vinod Solipuram,Ivy Abraham,Stephanie B Tsai,Maryam Zia,Melissa L Larson,Damiano Rondelli,Jessica K Altman,Wendy Stock,Irum Khan,Olatoyosi Odenike,Anand Ashwin Patel","doi":"10.1038/s41408-025-01366-x","DOIUrl":"https://doi.org/10.1038/s41408-025-01366-x","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"52 1","pages":"158"},"PeriodicalIF":12.8,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145235751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
